- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 08.11. | J&J angles Darzalex for first move into early-stage myeloma with trial win, FDA filing | ||
| 08.11. | AstraZeneca China fallout; Pfizer $1B plan in China; Incyte-Sun JAK dispute | ||
| 07.11. | Sparked by FDA expansion, Sarepta's Elevidys takes another leap in sales | ||
| 07.11. | Biologics CDMO Avid Bioservices to go private with $1.1B sale to Ampersand, GHO Capital | ||
| 07.11. | Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit | ||
| 07.11. | Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales | ||
| 07.11. | AGC Biologics aims to become 'safe harbor' for manufacturing clients as new CEO takes the reins | ||
| 07.11. | More turbulence at Aurinia as autoimmune drugmaker lays off 45% of workforce | ||
| 07.11. | AbbVie's Skyrizi rockets to top of TV drug ad spenders' list with single largest monthly total this year | ||
| 07.11. | Evotec offloads chemical API facility as part of its ongoing austerity program | ||
| 06.11. | Teva's generics and biosimilars fuel another booming quarter | ||
| 06.11. | After Lilly's GLP-1 sales fumble, Novo reports mixed results on Ozempic, Wegovy | ||
| 06.11. | More M&A, or a shake-up at the FDA? Pharma braces for Trump's return to the White House | ||
| 06.11. | Novavax coughs up $123.8M to settle COVID vaccine supply dispute with UK | ||
| 06.11. | Drugs for unmet needs and those from experienced companies had the best chance for successful launches in 2023: report | ||
| 05.11. | Analysts point to Syfovre 'nadir' after Apellis discloses disappointing quarter | ||
| 05.11. | AstraZeneca stock tanks over fears of expanding China fraud probe | ||
| 05.11. | Vertex's Casgevy breaks ground with 1st commercial patient infusions as company readies another major launch for 2025 | ||
| 05.11. | Arrowhead targets rare disease patients, pushing message that hope is on the horizon | ||
| 05.11. | Syndax inks $350M deal with Royalty Pharma for funding to launch 2 new drugs | ||
| 05.11. | Intra-Cellular's unstoppable Caplyta nails another trial, this time for relapse prevention in schizophrenia | ||
| 05.11. | Madrigal's Rezdiffra has launched a new MASH market, but 'tremendous change' is on the horizon | ||
| 05.11. | Accord wins £50M joint investment from UK to bolster local production of cancer, immunology drugs | ||
| 04.11. | Nektar pads wallet with $90M manufacturing plant sale to Ampersand | ||
| 04.11. | BioNTech reports surprising COVID vaccine sales in Q3 but tempers expectations for annual sales |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
